XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Sale of Pegzilarginase to Immedica (Details) - USD ($)
3 Months Ended 9 Months Ended
Jul. 27, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of in-process research & development asset       $ 0 $ 15,000,000
Gain recognized within operating expenses   $ 0 $ 14,609,000 $ 0 $ 14,609,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights To Pegzilarginase          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of in-process research & development asset $ 15,000,000.0        
Contingent consideration 100,000,000.0        
Carrying value of assets 0        
Gain recognized within operating expenses $ 14,600,000